--- title: "Renovaro Secures Key AI Patents, Strengthening Market Position in $20B Biomedical AI Sector | RENB Stock News" description: "Renovaro (NASDAQ: RENB) has announced the allowance of multiple U.S. patents that enhance its position in the $20B biomedical AI sector. The patents focus on federated learning technology for unbiased" type: "news" locale: "en" url: "https://longbridge.com/en/news/250444318.md" published_at: "2025-07-28T14:38:00.000Z" --- # Renovaro Secures Key AI Patents, Strengthening Market Position in $20B Biomedical AI Sector | RENB Stock News > Renovaro (NASDAQ: RENB) has announced the allowance of multiple U.S. patents that enhance its position in the $20B biomedical AI sector. The patents focus on federated learning technology for unbiased drug discovery and secure AI model training across decentralized healthcare datasets. This innovation supports partnerships in drug discovery, clinical trials, and precision medicine, addressing critical challenges in biomedical AI. CEO David Weinstein emphasized that expanding their IP footprint aligns with their vision to be a leader in next-generation biomedical research. Renovaro aims to improve treatment outcomes through AI-driven therapies and diagnostics. 07/28/2025 - 10:38 AM ***Strategic IP expansion protects federated learning technology driving pharma partnerships, biosecurity initiatives, and precision medicine growth*** Renovaro (NASDAQ:RENB), a precision-medicine technology company, today announced multiple U.S. patent allowances that significantly strengthen its competitive position in biomedical artificial intelligence. The new patents, including U.S. Application No. 18/058,732 for unbiased drug discovery predictions, expand Renovaro's growing IP portfolio anchored by foundational patents U.S. No. 11,379,757 and recently awarded Application No. 18/058,752. **Key Value Drivers:** - Protected Competitive Moat in federated learning for healthcare, with continuation filings extending IP coverage by establishing broad protection around harmonizing biomedical data and applying frameworks for AI-powered prediction of both beneficial and harmful treatment effects. - Enhances Partnership Opportunities by supporting high-value applications such as high-fidelity integration of heterogeneous datasets - including electronic health records (EHRs), imaging, genomics, and trial data - across distributed environments, directly enabling applications in drug discovery, clinical trials, rare disease research, and precision medicine. - Breakthrough in Federated and Secure AI Learning: The newly issued patent covers a novel federated learning architecture that enables advanced AI model training across decentralized healthcare datasets - such as those held by hospitals, research institutions, or biopharma partners - without requiring the exchange of sensitive raw data. This innovation provides robust bidirectional security, protecting both the underlying data sources and the integrity of the resulting AI models, and positions the company at the forefront of privacy-preserving AI in healthcare - Scalable and Reproducible AI Models designed for real-world deployment across heterogeneous data environments - an essential capability for future pharmaceutical and clinical partners. - Robust IP Pipeline: Multiple continuation filings underway, providing sustained innovation and patent coverage over time. Renovaro's newly allowed patents include innovations titled "*Methods, Systems, and Frameworks for Unbiased Data in Drug Discovery Predictions*" and "*Methods, Systems, and Frameworks for Federated Learning While Ensuring Bi-Directional Data Security*". These methods address critical pain points in biomedical AI, such as data sparsity, source heterogeneity, and lack of model transferability - paving the way for reproducible AI models in precision medicine. These filings also deepen the company's IP foundation by addressing key bottlenecks in the biomedical AI space - specifically, the integration of heterogeneous data such as EHRs, genomics, imaging, and clinical trial results into standardized pipelines capable of producing clinically relevant, reproducible insights. These capabilities are particularly critical for applications in rare disease research, trial optimization, and therapeutic targeting - areas with strong unmet needs and have high-value partnership potential. "Expanding our IP footprint in federated learning and AI-based data harmonization directly supports our long-term vision: to be the platform of choice for next-generation biomedical research and precision medicine," said David Weinstein, CEO, Renovaro. With additional patents pending and a portfolio designed to scale with evolving interoperability standards and regulatory demands, Renovaro continues to solidify its position as a platform company with durable, defensible technology in a market estimated to reach over $20B by 2030. **About Renovaro (NASDAQ: RENB)** Renovaro is a forward-looking biotechnology company harnessing the power of artificial intelligence and data science to develop innovative therapies and diagnostics in oncology, infectious disease, and autoimmune disorders. By integrating cutting-edge machine learning with biomedical research, Renovaro aims to dramatically improve treatment outcomes and enable earlier disease detection. **Forward-Looking Statements** This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking and subject to risks and uncertainties that could cause actual results to differ materially. Please refer to our filings with the SEC for a discussion of these risks. **Contact:** investors@renovaro.com www.renovarogroup.com **SOURCE:** Renovaro Biosciences View the original press release on ACCESS Newswire ### Related Stocks - [RENB.US - Lunai Bioworks](https://longbridge.com/en/quote/RENB.US.md) - [LNAI.US - Lunai Bioworks](https://longbridge.com/en/quote/LNAI.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Lunai Bioworks Inc. 的 SEC 10-Q 報告 | Lunai Bioworks Inc. 發佈了最新的 10-Q 表格報告，顯示財務表現有所改善，總運營費用從 5788 萬美元降至 513 萬美元。公司報告淨收入為 102 萬美元，相較於去年的 5146 萬美元虧損實現了顯著恢復。主要業務 | [Link](https://longbridge.com/en/news/276164384.md) | | Lunai Bioworks 推出 AI 平台，專注於疾病亞型的精準藥物發現 | Lunai Bioworks Inc. 已推出其 Augusta 平台，這是一種基於人工智能的藥物發現工具，能夠分析臨牀級患者數據以識別疾病亞型。此項創新旨在創造精準療法，降低臨牀失敗風險，並提高開發效率。演示文稿還討論了製藥行業面臨的挑戰 | [Link](https://longbridge.com/en/news/275478282.md) | | Lunai Bioworks 推出 AI 驅動的平台，以降低複雜疾病藥物發現過程中的風險 | Lunai Bioworks Inc.推出了一款名為 Augusta 的人工智能驅動平台，旨在提升複雜神經系統疾病的藥物發現。該平台利用先進的人工智能分析患者數據，識別不同的亞疾病，並將其與有效的治療方案匹配。這種方法旨在在活體系統中驗證藥 | [Link](https://longbridge.com/en/news/272454097.md) | | 美股盤前熱門交易：Lunai Bioworks 盤前漲 7.63%；標普全球盤前跌 6.12% | Lunai Bioworks 盤前漲 7.63%；標普全球盤前跌 6.12%；Abpro 盤前漲 81.58%；Quince Therapeutics 盤前漲 70.15%；哈弗蒂傢俱-A 盤前漲 39.25%。 | [Link](https://longbridge.com/en/news/275455934.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.